Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126394921 | 12639492 | 1 | I | 20160801 | 20160810 | 20160810 | EXP | US-AJANTA PHARMA USA INC.-1056141 | AJANTA PHARMA | WALLACE KL, FILIPEK RL, LA HOZ RM, WILLIAMSON JC. SUBTHERAPEUTIC VORICONAZOLE CONCENTRATIONS ASSOCIATED WITH CONCOMITANT DEXAMETHASONE: CASE REPORT AND REVIEW OF LITERATURE JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2016:41 (4):441-443, DOI: 10.1111. | 84.00 | YR | M | Y | 60.00000 | KG | 20160810 | PH | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126394921 | 12639492 | 1 | PS | VORICONAZOLE. | VORICONAZOLE | 1 | Oral | 206181 | 200 | MG | BID | ||||||||
| 126394921 | 12639492 | 2 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | Y | 0 | 4 | MG | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126394921 | 12639492 | 1 | Phaehyphomycosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126394921 | 12639492 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126394921 | 12639492 | Drug interaction | |
| 126394921 | 12639492 | Drug level below therapeutic | |
| 126394921 | 12639492 | Phaehyphomycosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |